<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_TECHNION-ISRAEL_Bcell_assay skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:TECHNION-ISRAEL/Bcell assay</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>navbar</TITLE></P><DIV class="container-fluid" style="margin-top:0px;"><DIV class="row"><DIV class="col-md-12"><NAV class="navbar navbar-inverse navbar-fixed-top " style=" z-index:800; position:fixed; margin:auto; width: 1180px ;"><DIV class="dropdown" style="padding-left: 100px;"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"><A href="https://2017.igem.org/Team:TECHNION-ISRAEL"> project </A></BUTTON><UL class="dropdown-menu" style=" margin: 0px;  left:78px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Description"> description </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Diseases"> Diseases &amp; Epitopes </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Design"><SPAN id="T">T</SPAN>ri-Display </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/delay_mechanism"><SPAN id="T">  T</SPAN>iming </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/kill_switch"><SPAN id="T">T</SPAN>erminate</A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Demonstrate"><SPAN id="T"> T</SPAN>olerance Assay </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"> wet lab 
							</BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 2px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/cell_lines"> cell lines </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Results"> results </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/hpc7"> hpc-7 results </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Notebook"> notebook </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Experiments"> protocols </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/InterLab"> interlab </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Parts"> parts </A></BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 2px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Parts"> parts </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Basic_Part"> basic part </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Composite_Part"> composite part </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Part_Collection"> part collection </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Improve">	 improvement </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown" style="width: auto"> human practices 
							</BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 18px; width: 170px;"><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/HP/Silver"> HP silver </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Engagement"> Education &amp; Public Engagement </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/HP/Gold_Integrated"> integrated HP </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/ethics"> ethics </A></LI></UL></DIV><DIV class="dropdown"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown"> judging
							</BUTTON><UL class="dropdown-menu" style="margin: 0px;  left: 2px "><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Safety"> safety </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Collaborations"> collaboration </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Achievements"> achievements </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Model"> modelling </A></LI></UL></DIV><DIV class="dropdown" style="padding-right: 100px;"><BUTTON class="dropdown-toggle" type="button" data-toggle="dropdown">team
							</BUTTON><UL class="dropdown-menu" style=" margin: 0px;  left: 2px;"><LI><A href=" https://2017.igem.org/Team:TECHNION-ISRAEL/Team"> members </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/Attributions"> attributions </A></LI><LI><A href="https://2017.igem.org/Team:TECHNION-ISRAEL/gallery"> gallery </A></LI></UL></DIV></NAV></DIV></DIV></DIV><P><TITLE>Bcell</TITLE></P><DIV class="container-fluid"><H2>  B cell Assay </H2><DIV class="row"><DIV class="col-md-2"><DIV class="side"><UL class="sidelist hidden-xs hidden-sm" style="width:auto; padding-top:0px;"><LI><A class="cell" href="#we"> WEHI-231 </A></LI><LI><A class="cell" href="#mo">Model Cells</A></LI><LI><A class="cell" href="#as"> Assay plasmid </A></LI><LI><A class="cell" href="#ab">Antibody display</A></LI><LI><A class="cell" href="#sc"> scFv </A></LI><LI><A class="cell" href="#fc"> scFv-FC fusion </A></LI><LI><A class="cell" href="#ex"> Experiment </A></LI></UL></DIV></DIV><DIV class="col-md-8"><DIV class="row"><DIV class="col-md-12"><P style="text-indent:inherit;">
							The assay x we developed is meant to serve as proof of concept for our system and to demonstrate the following:
							</P><OL class="B assay" style="font-size: 18px;	line-height: 35px;"><LI> Our system displays the chosen proteins correctly on the cellular membrane. </LI><LI> Displayed proteins can interact with B cell receptors and activate them. </LI><LI> Immature B cells (such as the ones we are targeting within the bone marrow) undergo apoptosis as a result of exposure to our antigen/epitope presenting cells. </LI></OL><H4> Materials and Methods </H4></DIV></DIV><DIV class="row vertical-align"><DIV class="col-md-9"><H5 id="we"> WEHI-231 </H5><P> WEHI-231 is an immature murine B cell lymphoma cell line. This cell line was chosen specifically for our assay as it can provide valuable information about our system. Like all immature B cells, WEHI cells constitutively display immature antibodies of the IgM isotype on their membrane. 
							</P></DIV></DIV><DIV class="row"><DIV class="col-md-12"><P>
							 Multiple studies have shown							 <SUP id="cite ref-1 " class="reference"><A href="#ref1" original-title="">[1] </A></SUP>
							that when WEHI cells are exposed to anti-IgM antibodies, their B cell receptors (The membrane bound antibodies, also known as BCRs) are activated, and the cells undergo apoptosis. This process has been accepted as analogous to the process of 
							 <A target="_blank" href="https://2017.igem.org/Team:TECHNION-ISRAEL/Description#imt">Central Tolerance </A><SUP id="cite ref-1 " class="reference"><A href="#ref1" original-title="">[1] </A></SUP><SUP id="cite ref-2 " class="reference"><A href="#ref2" original-title="">[2] </A></SUP>
							within the bone marrow, wherein immature B cells that are exposed to antigen capable of activating their BCRs undergo apoptosis <STRONG>(figure 1)</STRONG>. While the antibodies displayed on the membrane of each WEHI cell have different affinities, they all possess the same constant IgM isotype which can be targeted with anti-IgM antibodies. These antibodies can activate and cross-link all the BCRs on the WEHI cells in a nonspecific manner, but the resulting intracellular cascade is identical to natural BCR activation.	
							</P><DIV class="row"><DIV class="col-md-offset-1 col-md-10"><P style="text-align: center;"><STRONG>Figure 1: </STRONG>central tolerance </P></DIV></DIV></DIV></DIV><DIV class="row"><DIV class="col-md-9"><H5 id="mo"> HEK293 </H5><P style="text-indent:inherit;"> Throughout our project we used <A target="_blank" href="https://2017.igem.org/Team:TECHNION-ISRAEL/cell_lines"> HEK-293</A> as a HSC model. 
							</P></DIV></DIV><DIV class="row"><DIV class="col-md-12"><H5 id="as"> Assay plasmid </H5><P>
							This plasmid contains our display system, but instead of an epitope we are displaying an anti-IgM antibody. This protein is designed to bind the IgM portion of the antibodies that are on the WEHI cells. We believe that this serves as a perfect model for our system wherein our epitopes are meant to bind the BCRâ€™s of immature B cells within the bone marrow.
							</P><DIV class="row"><DIV class="col-md-offset-1 col-md-10"><P style="text-align: center;"><STRONG>Figure 2: </STRONG> modified gBlock</P></DIV></DIV><H5 id="ab"> Antibody display </H5><P style="text-indent:inherit;">
							For our assay to work, we need to display a functioning antibody on the membrane of our model cells. This is a herculean task for many reasons:
							</P><OL class="displayA" style="font-size: 17px;	line-height: 35px;"><LI>Antibodies are complex protein heterodimers consisting of four separate proteins (two light chains and two heavy chains) from two completely different loci in the genome. Our platform is plasmid based and therefore less compatible with polycistronic genes.</LI><LI>Antibodies undergo many post-translational processes that are unique to B cells in order to become functional. Our model cells are not B cells and therefore lack this ability.</LI><LI>Since our display system uses a different transmembrane domain than naturally occurring membrane antibodies, correct folding of the antibody is even more unlikely. </LI></OL><P>
							As well as many other issues. After laborious research and multiple consultations with antibody display experts (<A target="_blank" href="https://2017.igem.org/Team:TECHNION-ISRAEL/HP/Silver">Prof. Yoram Reiter</A>) we set out to test two systems for membrane antibody display, namely, scFv display and scFv-FC fusion display.
							</P></DIV></DIV><DIV class="row vertical-align"><DIV class="col-md-9"><H5 id="sc"> scFv </H5><P>Single Chain Variable Fragment (scFv) is a fusion protein consisting of both the heavy and light variable chains of an antibody connected by a short linker peptide <STRONG>(figure 3)</STRONG>. After exhausting nearly all research options and crafting plans to create an anti-IgM scFv ourselves, we discovered a 
								paper <SUP id="cite ref-3 " class="reference"><A href="#ref3" original-title="">[3] </A></SUP> in which an anti-IgM scFv sequence had already been created and tested. We then ordered a Gblock (<STRONG>figure 2</STRONG>) from IDT with the scFv sequence modified to fit our existing construct.
								</P></DIV><DIV class="col-md-3"><P style="text-align: center;"><STRONG> Figure 3: </STRONG> antibody</P></DIV></DIV><DIV class="row"><DIV class="col-md-10"><H5 id="fc"> scFv-FC fusion </H5><P>Singe Chain Variable Fragment â€“ FC fusion is a protein that consists of a scFv attached to the FC region of an IgG antibody (Hinge-CH2-CH3) <STRONG>(figure 4)</STRONG>. This amalgam leads to dimerization of the antibody fragments on the membrane which increases the stability and half-life of the synthetic antibody while also creating more distance from the membrane allowing for less steric hindrance <STRONG>(figure 5)</STRONG>. Additionally the dimeric form of the antibody is more likely to allow for BCR cross linking of the WEHI cells which is necessary for apoptosis. We made two variants of this gene, one using the Hinge-CH2-CH3 region from rattus norvegicus, the source of our scFv, and another using the same region from human origin as has been described in publications
								 <SUP id="cite ref-4 " class="reference"><A href="#ref4" original-title="">[4] </A></SUP>.
								</P></DIV><DIV class="col-md-2"><P style="text-align: center;"><STRONG>Figure 4: </STRONG> Singe Chain Variable </P></DIV></DIV><DIV class="row"><DIV class="col-md-offset-1 col-md-10"><P style="text-align: center;"><STRONG> Figure 5: </STRONG> dimerization of the antibody   </P></DIV></DIV><DIV class="row"><DIV class="col-md-12"><H5 id="ex"> Experiment </H5><P>HEK293 cells, transfected with our assay-plasmid, were cocultured with WEHI-231 cells <STRONG>(figure 6)</STRONG>. Apoptosis of WEHI cells was quantified by flow cytometry measurement using Annexin V and PI from an Invitrogen Dead Cell Apoptosis Kit
								<SUP id="cite ref-5 " class="reference"><A href="#ref5" original-title="">[5] </A></SUP>
									according to the manufacturerâ€™s instructions. Measurements are taken at 0 hours, 24 hours and 48 hours and compared with a control of WEHI cells cocultured with non-transfected HEK293 cells. In previous experiments<SUP id="cite ref-1 " class="reference"><A href="#ref1" original-title="">[1] </A></SUP>
, 30% of the WEHI cells underwent apoptosis as a result of exposure to anti-IgM. If similar results are achieved in the cocultured WEHI cells, it can be concluded that our system presents antigen correctly and allows for BCR binding, cross-linking and activation. This will serve as proof of concept for our system and allow us to pursue animal experimentation licensure in the future. 
									</P></DIV></DIV><DIV class="row"><DIV class="col-md-offset-1 col-md-10"><P style="text-align: center;"><STRONG>  Figure 6: </STRONG> A model HSC transfected with our assay plasmid inducing apoptosis in an immature B cell model by cross-linking 
									the BCRs</P></DIV></DIV><DIV class="row"><DIV class="col-md-12"><DIV class="references"><OL><LI id="ref1">Gottschalk, Alexander R., and JosÃ© QuintÃ¡ns. &quot;Apoptosis in B lymphocytes: the WEHI-231 perspective.&quot;   <I> Immunology &amp; Cell Biology </I> 73.1 (1995).</LI><LI id="ref2"> Page, DAWNE M., and ANTHONY L. DeFranco. &quot;Antigen receptor-induced cell cycle arrest in WEHI-231 B lymphoma cells depends on the duration of signaling before the G1 phase restriction point.&quot; <I>Molecular and cellular biology </I>10.6 (1990): 3003-3012.</LI><LI id="ref3"> Lee, Timothy K., et al. &quot;Production of engineered IgM-binding single-chain antibodies in Escherichia coli.&quot; <I>Journal of Industrial Microbiology &amp; Biotechnology </I>14.5 (1995): 371-376.</LI><LI id="ref4">JÃ¤ger, Volker, et al. &quot;High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells.&quot; <I>BMC biotechnology </I>13.1 (2013): 52.</LI><LI id="ref5"><I> Thermo Fisher Scientific</I>, www.thermofisher.com/order/catalog/product/V13242.
</LI></OL></DIV></DIV></DIV></DIV></DIV></DIV><P><TITLE>My First Website</TITLE></P><DIV class="footer"><DIV class="container-fluid"><DIV class="row"><DIV class="col-md-offset-1 col-md-10"><DIV class="row"><DIV class="col-md-4 nopadding"><DIV class="location"><P style="text-indent:inherit; margin-top: 30px; padding-bottom:15px;color:  #ffffff; 	font-family:  'Quicksand', sans-serif; 	font-size: 14px; 	line-height:25px; 	text-align: unset;">
											
							Department of Biotechnology &amp; Food Engineering
							
							
							Technion â€“ Israel Institute of Technology
							
							
							Haifa 32000, Israel
							</P></DIV></DIV><DIV class="col-md-offset-3 col-md-3"><DIV class="contact" style="margin-top: 20px;"><UL><P style=" text-indent:inherit; margin-top: 5px; color:  #ffffff; font-family: 'Quicksand', sans-serif;	font-size: 14px;">
									igem.technion.2017@gmail.com
									</P></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>